AccuMed buys up remaining share of Oncometrics
This article was originally published in Clinica
AccuMed is to acquire the remaining one-third of Xillix' subsidiary, Oncometrics Imaging, that it does not already own. Chicago-based AccuMed obtained the two-thirds share in Oncometrics in the middle of 1996 to commercialise its quantitative microscopy imaging technology and the results of research into early cancer detection (see Clinica No 714, p 12). The terms of the recent transaction were not disclosed.
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.